Beyond Air Publishes Review on High-Dose Inhaled Nitric Oxide
Beyond Air commented on the publication of an independent review article providing the most comprehensive overview to date of high-dose inhaled nitric oxide, iNO, delivered at concentrations well above the FDA-approved 20 ppm, and presenting mounting evidence that high-dose iNO may function as a novel broad-spectrum antimicrobial therapy for a wide range of respiratory infections. Titled "The therapeutic potential of high-dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions," the article was published in Intensive Care Medicine Experimental, a peer-reviewed, open-access journal of the European Society of Intensive Care Medicine, published by Springer Nature Switzerland AG. "We are excited to see the scientific community increasingly recognize high-dose iNO as a potential game-changing antimicrobial platform for respiratory infections," said Steve Lisi, Chief Executive Officer of Beyond Air. "A growing collection of studies shows that high-dose iNO can address pathogens and clinical challenges that current therapies are unable to treat. This most recent article builds on the momentum of our own clinical programs that have demonstrated promising signals in NTM, bronchiolitis, community-acquired pneumonia, and COVID-19. We believe the publication of this article will serve as a catalyst for new scientific research and accelerate the clinical development of high-dose iNO as a potential transformative treatment modality for pulmonary indications."
